We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cognito Touts Its Therapy’s Ability to Reduce Alzheimer’s White Matter Atrophy
Cognito Touts Its Therapy’s Ability to Reduce Alzheimer’s White Matter Atrophy
Cognito Therapeutics’ gamma sensory stimulation therapy reduced white matter atrophy in the brains of patients with Alzheimer’s disease in a six-month study, the company announced at the Alzheimer’s Association International Conference 2022 in San Diego.